- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941089
Added Value of HR-pQCT in Detecting Calcium Deposits in Rheumatoid Arthritis (HAND-QCT-RA)
Added Value of HR-pQCT: Detecting and Characterizing Calcium Deposits Suggestive of CPPD in the Hand and Wrist of Rheumatoid Arthritis Patients (HAND-QCT-RA)
The goal of this clinical trial is to learn if a high-resolution computed tomography scan (HR-pQCT) can detect and describe calcium crystal deposits in the hands and wrists of adults with rheumatoid arthritis (RA). The main questions it aims to answer are:
- How often does the HR-pQCT scan detect calcium crystal deposits in the hand and wrist joints of people with RA?
- Can the HR-pQCT scan find calcium deposits that standard tests (x-rays and ultrasound) miss? Researchers will compare scan results from participants with RA to results from participants with known calcium pyrophosphate deposition (CPPD) and participants without joint inflammation.
During a single clinic visit, participants will:
- Have standard x-rays of their hands and wrists
- Have a routine ultrasound of their hands and wrists
- Have an HR-pQCT scan of their wrist and finger joints, which takes about 15 to 20 minutes and uses a very low dose of radiation
Study Overview
Status
Intervention / Treatment
Detailed Description
Calcium pyrophosphate deposition (CPPD) disease is an underdiagnosed crystal arthritis that frequently mimics rheumatoid arthritis (RA) or coexists with it, particularly when presenting as chronic inflammatory polyarthritis involving the wrists and metacarpophalangeal (MCP) joints. Although synovial fluid crystal identification remains the reference standard, aspiration of small hand joints is often technically unfeasible or non-diagnostic. Consequently, diagnosis relies heavily on conventional radiography and musculoskeletal ultrasonography, both of which suffer from recognized limitations in detecting subtle or early calcifications.
High-resolution peripheral quantitative computed tomography (HR-pQCT) provides superior spatial resolution and volumetric bone microarchitecture assessment. This multicenter, cross-sectional pilot study investigates whether HR-pQCT can enhance the detection and structural characterization of CPPD-suggestive calcium deposits within the triangular fibrocartilage complex (TFCC) and 2nd/3rd MCP hyaline cartilage.
To enable combined multi-site analysis, cross-calibration between the two participating tertiary centers (IRCCS Istituto Ortopedico Rizzoli, utilizing a second-generation Scanco XtremeCT II system, and AOUI Verona, utilizing a RAR Medical Devices ArtiCAT cone-beam system) is conducted using the European Forearm Phantom (EFP; QRM AG). Scans follow harmonized volumetric acquisition protocols based on international recommendations (SPECTRA group). All imaging acquisitions (radiographs, ultrasound, and HR-pQCT) are evaluated independently and in a double-blinded manner by trained musculoskeletal radiologists and rheumatologists.
At the patient level, a participant is classified as positive if at least one calcium deposit is detected in any of the examined joints. Because each participant undergoes imaging across multiple anatomical sites (the TFCC of the wrist and the 2nd and 3rd metacarpophalangeal joints of both hands), observations from the same individual are correlated. To account for this within-subject correlation without losing anatomical detail, site-specific analyses will be conducted using mixed-effects models or generalized estimating equations (GEE).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jacopo Ciaffi
- Phone Number: +39 051.6445505
- Email: jacopo.ciaffi@ior.it
Study Locations
-
-
Bologna
-
Bologna, Bologna, Italy, 40136
- IRCCS Istituto Ortopedico Rizzoli - SSD Medicina e Reumatologia
-
-
Verona
-
Verona, Verona, Italy, 37134
- Azienda Ospedaliera Universitaria Integrata di Verona - UO di Reumatologia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Rheumatoid Arthritis (RA) Cohort:
- Age ≥ 60 years
- Diagnosis of Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria
- Clinical diagnosis confirmed by an expert rheumatologist
- Current or past inflammatory involvement of the hand and/or wrist
- Written informed consent obtained
Calcium Pyrophosphate Deposition (CPPD) Cohort:
- Age ≥ 60 years
- Established diagnosis of CPPD based on synovial fluid crystal analysis and/or imaging findings compatible with current classification criteria
- Current or past inflammatory involvement of the hand and/or wrist
- Written informed consent obtained
Control Cohort (Non-inflammatory Controls):
- Age ≥ 60 years
- Outpatient evaluation at one of the participating centers for a condition not suggestive of CPPD, rheumatoid arthritis, erosive osteoarthritis, or other inflammatory joint diseases
- Clinical indication for conventional radiography of the hand and/or wrist as part of routine clinical practice
- Absence of past or present hand or wrist joint swelling suggestive of inflammatory arthritis
- Written informed consent obtained
Exclusion Criteria:
All Cohorts:
- Contraindications to CT-based imaging (including the inability to immobilize the hand and wrist during image acquisition)
- Known causes of secondary CPPD (e.g., hyperparathyroidism, hemochromatosis, hypomagnesemia, hypophosphatasia)
- Presence of hand/wrist prosthesis or osteosynthesis material interfering with image acquisition
- Inability to provide written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Rheumatoid Arthritis (RA) Cohort
Patients with RA and current or prior hand/wrist involvement (n = 60). |
High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.
Other Names:
|
|
Active Comparator: Healthy / Non-inflammatory Controls
Subjects undergoing hand/wrist imaging for non-inflammatory conditions (n = 60). |
High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.
Other Names:
|
|
Active Comparator: CPPD Positive Control Cohort
Patients with proven CPPD disease (n = 20). |
High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in rheumatoid arthritis
Time Frame: Baseline (single imaging visit)
|
Percentage of participants with rheumatoid arthritis with at least one calcium deposit suggestive of CPPD detected by HR-pQCT at the triangular fibrocartilage complex (TFCC) and/or the 2nd-3rd metacarpophalangeal (MCP) joints. |
Baseline (single imaging visit)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of HR-pQCT-positive cases missed by conventional imaging
Time Frame: Baseline (single imaging visit)
|
Percentage of participants with no CPPD-suggestive calcium deposits on either conventional radiography or ultrasonography who have at least one CPPD-suggestive calcium deposit on HR-pQCT. |
Baseline (single imaging visit)
|
|
Agreement between conventional radiography and HR-pQCT for CPPD-suggestive calcium deposits
Time Frame: Baseline (single imaging visit)
|
Cohen's kappa coefficient for agreement between conventional radiography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits. |
Baseline (single imaging visit)
|
|
Agreement between ultrasonography and HR-pQCT for CPPD-suggestive calcium deposits
Time Frame: Baseline (single imaging visit)
|
Cohen's kappa coefficient for agreement between ultrasonography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits. |
Baseline (single imaging visit)
|
|
Agreement between combined conventional imaging and HR-pQCT for CPPD-suggestive calcium deposits
Time Frame: Baseline (single imaging visit)
|
Cohen's kappa coefficient for agreement between combined conventional imaging and HR-pQCT. A participant is classified as positive on combined conventional imaging if deposits are detected on radiography, ultrasonography, or both. |
Baseline (single imaging visit)
|
|
Volume of CPPD-suggestive calcium deposits on HR-pQCT
Time Frame: Baseline (single imaging visit)
|
Total volume of CPPD-suggestive calcium deposits per participant, measured on HR-pQCT (mm³), in participants with at least one deposit. |
Baseline (single imaging visit)
|
|
Volumetric density of CPPD-suggestive calcium deposits on HR-pQCT
Time Frame: Baseline (single imaging visit)
|
Mean volumetric density of CPPD-suggestive calcium deposits (mg HA/cm³), measured on HR-pQCT, in participants with at least one deposit. |
Baseline (single imaging visit)
|
|
Anatomical distribution of CPPD-suggestive calcium deposits on HR-pQCT
Time Frame: Baseline (single imaging visit)
|
Percentage of participants with deposits at the TFCC only, at the 2nd-3rd MCP joints only, or at both sites, among participants with at least one deposit on HR-pQCT. |
Baseline (single imaging visit)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in seronegative vs seropositive rheumatoid arthritis
Time Frame: Baseline (single imaging visit)
|
Percentage of participants with at least one CPPD-suggestive calcium deposit on HR-pQCT, reported separately for seronegative participants (RF- and ACPA-negative) and seropositive participants. |
Baseline (single imaging visit)
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Filippou G, Adinolfi A, Cimmino MA, Scire CA, Carta S, Lorenzini S, Santoro P, Sconfienza LM, Bertoldi I, Picerno V, Di Sabatino V, Ferrata P, Galeazzi M, Frediani B. Diagnostic accuracy of ultrasound, conventional radiography and synovial fluid analysis in the diagnosis of calcium pyrophosphate dihydrate crystal deposition disease. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):254-60. Epub 2016 Feb 9.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-8. doi: 10.1136/ard.2010.138461.
- Krekeler M, Baraliakos X, Tsiami S, Braun J. High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. RMD Open. 2022 Jun;8(2):e002383. doi: 10.1136/rmdopen-2022-002383.
- Tedeschi SK, Becce F, Pascart T, Guermazi A, Budzik JF, Dalbeth N, Filippou G, Iagnocco A, Kohler MJ, Laredo JD, Smith SE, Simeone FJ, Yinh J, Choi H, Abhishek A. Imaging Features of Calcium Pyrophosphate Deposition Disease: Consensus Definitions From an International Multidisciplinary Working Group. Arthritis Care Res (Hoboken). 2023 Apr;75(4):825-834. doi: 10.1002/acr.24898. Epub 2022 Nov 23.
- Barnabe C, Feehan L; SPECTRA (Study GrouP for XTrEme-CT in RA). High-resolution peripheral quantitative computed tomography imaging protocol for metacarpophalangeal joints in inflammatory arthritis: the SPECTRA collaboration. J Rheumatol. 2012 Jul;39(7):1494-5. doi: 10.3899/jrheum.120218. No abstract available.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Crystal Arthropathies
- Musculoskeletal Diseases
- Arthritis
- Joint Diseases
- Rheumatic Diseases
- Metabolic Diseases
- Connective Tissue Diseases
- Autoimmune Diseases
- Immune System Diseases
- Calcium Metabolism Disorders
- Nutritional and Metabolic Diseases
- Skin and Connective Tissue Diseases
- Arthritis, Rheumatoid
- Calcinosis
- Chondrocalcinosis
Other Study ID Numbers
- HAND-QCT-RA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.